

Diese Meldung kann unter <http://www.presseportal.de/pm/64962/1002055/inovelon-r-a-new-treatment-for-lennox-gastaut-syndrome-launched-in-europe> abgerufen werden.

Eisai Europe Limited

Inovelon(R) A New Treatment for Lennox-Gastaut Syndrome Launched in Europe

15.06.2007 - 10:40 Uhr, Eisai Europe Limited

London (ots/PRNewswire) -

- First Treatment Licensed Specifically for LGS Offers New Hope for Patients With Epilepsy

Eisai Europe Limited, (Headquarters: London, President Yutaka Tsuchiya) today announced the launch in Germany and Scandinavia of its new anti-epileptic agent Inovelon (rufinamide) indicated for adjunctive therapy in Lennox-Gastaut Syndrome (LGS).

Inovelon, a structurally novel compound, is the first treatment licensed by the European Medicines Agency (EMA) specifically for LGS, a severe form of generalised epilepsy that develops in early childhood.

Symptoms of LGS include a variety of seizure types, with tonic-atonic seizures being the most common. Atonic seizures (rapid loss of muscle tone and consciousness), and tonic seizures (where muscles contract continuously typically producing a stiffening of the legs and arms) lead to the sudden falls seen in LGS patients known as 'drop attacks'. Absence seizures (staring spells) and myoclonic seizures (sudden muscle jerks) are also commonly observed. All children with LGS will experience varying degrees of developmental delay and behavioral problems.

In a placebo-controlled study Inovelon was found to produce a median reduction in seizure frequency of 42.5% (p=

Originaltext:

Eisai Europe Limited

Pressemappe:

<http://www.presseportal.de/pm/64962/eisai-europe-limited>

Pressemappe als RSS:

http://presseportal.de/rss/pm_64962.rss2